Etiology of Parkinson's disease

Canadian Journal of Neurological Sciences

Volumn 26, Issue SUPPL. 2, 1999, Pages

  Stoessl, A Jon ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; NEUROTOXIN; SONIC HEDGEHOG PROTEIN;

AGING; APOPTOSIS; ARTICLE; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; INFECTION; MITOCHONDRIAL RESPIRATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTROPISM; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032786931     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100000032     Document Type: Article

References (122)

1. Rajput AH. Frequency and cause of Parkinson's disease. Can J Neurol Sci 1992; 19 (Suppl. 1): 103-107.
2. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in Parkinsonism-a prospective study. Can J Neurol Sci 1991; 18: 275-278.
3. Semchuk KM, Love EJ. Effects of agricultural work and other proxderived case-control data on Parkinson's disease risk estimates. Am J Epidemiol 1995; 141: 747-754.
4. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33: 815-824.
5. Vieregge P, Schiffke KA, Friedrich HJ, Muller B, Ludin HP. Parkinson's disease in twins. Neurology 1992; 42: 1453-1461.
6. Burn DJ, Mark MH, Playford ED, et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992; 42: 1894-1900.
7. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson disease in twins: an etiologic study. JAMA 1999; 281: 341-346.
8. Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994; 36: 659-661.
9. Golbe LI, Di Iorio G, Bonavita, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990; 27: 276-282.
10. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the asynuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
11. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genetics 1998; 18: 106-108.
12. Scott WK, Staijich JM, Yamaoka LH, et al. Genetic complexity and Parkinson's disease. Science 1997; 277: 387-388.
13. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. Genetic complexity and Parkinson's disease. Science 1997; 277: 388-389.
14. Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations in the coding region of the alpha-synuclein gene in pathologically proven Parkinson's disease. Neurology 1998; 50: 1136-1137.
15. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genetics 1998; 18: 262-265.
16. Swerdlow RH, Parks, JK, Miller SW et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 1996; 40: 663-671.
17. Shimoda-Matsubayashi S, Hattori T, Matsumine H, et al. Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control. Neurology 1997; 49: 1257-1262.
18. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
19. Leroy E, Boyer R, Auburger G et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-452.
20. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993; 33: 368-372.
21. Parboosingh JS, Rousseau M, Rogan F, et al. Absence of mutations in Superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch Neurol 1995; 52: 1160-1163.
22. Gasser T, Wszolek ZK, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994; 36: 387-396.
23. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985; 35: 841-845.
24. Jendroska K, Olasode BJ, Daniel SE, et al. Incidental Lewy body disease in black Africans. Lancet 1994; 344: 882-883.
25. Wang SJ, Fuh JL, Teng EL, et al. A door-to-door survey of Parkinson's disease in a Chinese population in Kinmen. Arch Neurol 1996; 53: 66-71.
26. Zhang Z-X, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiol 1993; 12: 195-208.
27. Calne S, Schoenberg B, Martin W, Uitti RJ, Spencer P, Calne DB. Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 1987; 14: 303-305.
28. Rajput AH, Uitti RJ, Stern W, et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci 1987; 14: 414-418.
29. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology 1993; 43: 1150-1158.
30. Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993; 43: 1693-1697.
31. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993; 43: 1173-1180.
32. Stern M, Dulaney E, Gruber SB, et al. The epidemiology of Parkinson's disease: a case-control study of young-onset and old-onset patients. Arch Neurol 1991; 48: 903-907.
33. Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994; 36: 100-103.
34. Wang W-z, Fang X-h, Cheng X-m, Jiang D-h, Lin Z-j. A case-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. Neuroepidemiology 1993; 12: 209-218.
35. Chaturvedi S, Ostbye T, Stoessl AJ, Merskey H, Hachinski V. Environmental exposures in elderly Canadians with Parkinson's disease. Can J Neurol Sci 1995; 22: 232-234.
36. Godwin-Austen RG, Leigh PN, Marmot MG, Stern GM. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry 1982; 45: 577-581.
37. Mayeux R, Tang MX, Marder K, Cote LJ, Stern Y. Smoking and Parkinson's disease. Mov Disord 1994; 9: 207-212.
38. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995; 45: 1041-1051.
39. Riggs JE. Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. Clin Neuropharm 1992; 15: 88-99.
40. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994; 139: 1129-1138.
41. Williams DB, Annegers JF, Kokmen E, O'Brien PC, Kurland LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology 1991; 41: 1554-1557.
42. Lin SK, Lu CS, Vingerhoets FJG, et al. Isolated involvement of substantia nigra in acute transient Parkinsonism: MRI and PET observations. Parkinsonism Rel Disord 1995; 1: 67-73.
43. Takahashi M, Yamada T, Nakajima S, Nakajima K, Yamamoto T, Okada H. The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med 1995; 181: 2161-2169.
44. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease of brains. Neurology 1988; 38: 1285-1291.
45. Defazio G, Daltoso R, Benvegnu D, Minozzi MC, Cananzi AR, Leon A. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res 1994; 633: 206-212.
46. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977; 34: 33-35.
47. Kish SJ, Shannak K, Rajput A, Deck JHN, Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992; 58: 642-648.
48. Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994; 117: 501-507.
49. Calne DB. Is idiopathic parkinsonism the consequence of an event or a process? Neurology 1994; 44: 4-10.
50. Schulzer M, Lee CS, Mak EK, Vingerhoets FJG, Calne DB. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994; 117: 509-516.
51. Hallman H, Lange J, Olson L, Stromberg I, Jonsson G. Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem 1985; 44: 117-127.
52. Willis GL, Donnan GA. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 1987; 402: 269-274.
53. Kalaria RN, Mitchell MJ, Harik SI. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proc Natl Acad Sci USA 1987; 84: 3521-3525.
54. Giovanni A, Sonsalla PK, Heikkila RE. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 2. Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Therap 1994; 270: 1008-1014.
55. Heikkila RE, Nicklas WJ, Duvoisin RC. Dopaminergic toxicity after the stereotaxic adminstration of the 1-methyl-4-phenylpyridinium ion (MPP+) to rats. Neurosci Lett 1985; 59: 135-140.
56. Bradbury AJ, Costall B, Domeny AM, et al. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature 1986; 319: 56-57.
57. Gerlach M, Riederer P, Przuntek H, Youdim MBH. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 1991; 208: 273-286.
58. McNaught KS, Thull U, Carrupt PA, et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 1995; 50: 1903-1911.
59. Maruyama W, Naoi M, Kasamatsu T, et al. An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J Neurochem 1997; 69: 322-329.
60. Turski L, Bressler K, Rettig K-J, Loschmann P-A, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349: 414-418.
61. Sawada H, Shimohama S, Tamura Y, Kawamura T, Akaike A, Kimura J. Methylphenylpyridinium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J Neurosci Res 1996; 43: 55-62.
62. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38: 357-366.
63. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996; 8: 1408-1414.
64. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46: 1551-1556.
65. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36: 348-355.
66. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 38-44.
67. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994; 36: 356-361.
68. Olanow CW, Cohen G, Perl DP, Marsden CD. Role of iron and oxidant stress in the normal and parkinsonian brain. Ann Neurol 1992; 32: S1-S145.(Abstract)
69. Youdim MBH, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 1993; 8: 1-12.
70. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
71. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn Superoxide dismutase mutation. Science 1994; 264: 1772-1775.
72. Beckman JS, Chen J, Crow JP, Ye YZ. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 1994; 103: 371-380.
73. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114: 1953-1975.
74. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 1994; 36: 876-881.
75. Toffa S, Kunikowska GM, Zeng BY, Jenner P, Marsden CD. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm 1997; 104: 67-75.
76. Wullner U, Loschmann PA, Schulz JB, et al. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurons. NeuroReport 1996; 7: 921-923.
77. Li YH, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 1997; 19: 453-463.
78. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994; 9: 92-97.
79. Sanchez-Ramos JR, Overvik E, Ames BN. A marker of oxyradicalmediated DNA damage (8-hydroxy-2'-deoxyguanosine) is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration 1994; 3: 197-204.
80. DiMauro S. Mitochondrial involvement in Parkinson's disease: the controversy continues. Neurology 1993; 43: 2170-2172.
81. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical reappraisal. Mov Disord 1994; 9: 125-138.
82. Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992; 12: 1658-1667.
83. Ferrante RJ, Schulz JB, Kowall NW, Beall MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997; 753: 157-162.
84. Calne DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol 1992; 32: 799-803.
85. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804-812.
86. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992; 42: 2241-2250.
87. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29-36.
88. Dexter DT, Brooks DJ, Harding AE, et al. Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. Ann Neurol 1995; 35: 298-303.
89. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures. J Neurochem 1997; 69: 1398-1408.
90. Agid Y. Levodopa. Is toxicity a myth? Neurology 1998; 50: 858-863.
91. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43: 561-575.
92. Rajput AH, Uitti RJ, Rajput A, Offord KP. Timely levodopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Rel Disord 1997; 3: 159-165.
93. Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: PRADO-study discontinued. Eur J Clin Pharmacol 1992; 43: 357-363.
94. Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230-232.
95. Lin L-FH, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-1132.
96. Tomac A, Widenfalk J, Lin L-FH, et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci USA 1995; 92: 8274-8278.
97. Tomac A, Lindquist E, Lin L-FH, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995; 373: 335-339.
98. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995; 373: 339-341.
99. Lindner MD, Winn SR, Baetge EE, et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 1995; 132: 62-76.
100. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838-841.
101. Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 1997; 94: 2019-2024.
102. Wang MZ, Jin P, Bumcrot DA, et al. Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog protein. Nature Medicine 1995; 1: 1184-1188.
103. Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998; 18: 4929-4937.
104. Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurrl-deficient mice. Science 1997; 276: 248-250.
105. Tooyama I, Kawamata T, Walker D, et al. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 1993; 43: 372-376.
106. Gagliardini V, Fernandez P-A, Lee RKK, et al. Prevention of vertebrate neuronal death by the crmA gene. Science 1994; 263: 826-828.
107. Bump NJ, Hackett M, Hugunin M, et al. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 1995; 269: 1885-1888.
108. Milligan CE, Prevette D, Yaginuma H, et al. Peptide inhibitors of the ICE protease family arrest programmed cell death of motoneurons in vivo and in vitro. Neuron 1995; 15: 385-393.
109. Barinaga M. Death by dozens of cuts. Science 1998; 280: 32-34.
110. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996; 137: 120-123.
111. Tompkins MM, Basgall EJ, Zamrini E, Hill WD. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997; 150: 119-131.
112. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997; 12: 25-31.
113. Kosel S, Egensperger R, vonEitzen U, Mehraein P, Graeber MB. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol 1998; 93: 105-108.
114. Mogi M, Harada M, Kondo T, et al. Bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 1996; 215: 137-139.
115. Troy CM, Shelanski ML. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc Natl Acad Sci USA 1994; 91: 6384-6387.
116. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AHV. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994; 63: 1987-1990.
117. Ziv I, Melamed E, Nardi N, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994; 170: 136-140.
118. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997; 77: 1037-1048.
119. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995; 92: 7162-7166.
120. Estevez AG, Radi R, Barbeito L, Shin JT, Thompson JA, Beckman JS. Peroxynitrite-induced cytotoxicity in PC12 cells: evidence for an apoptotic mechanism differentially modulated by neurotrophic factors. J Neurochem 1995; 65: 1543-1550.
121. Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 1997; 94: 7531-7536.
122. Patil N, Cox DR, Bhat D, Faham M, Myers RM, Peterson AS. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation. Nature Genetics 1995; 11: 126-129.